These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

442 related items for PubMed ID: 34732043

  • 21. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
    Kapoor S, Natarajan K, Baldwin PR, Doshi KA, Lapidus RG, Mathias TJ, Scarpa M, Trotta R, Davila E, Kraus M, Huszar D, Tron AE, Perrotti D, Baer MR.
    Clin Cancer Res; 2018 Jan 01; 24(1):234-247. PubMed ID: 29074603
    [Abstract] [Full Text] [Related]

  • 22. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.
    Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, Boyd KL, Strickland SA, Sensintaffar J, Hogdal LJ, Ayers GD, Olejniczak ET, Fesik SW, Savona MR.
    Cancer Discov; 2018 Dec 01; 8(12):1566-1581. PubMed ID: 30185627
    [Abstract] [Full Text] [Related]

  • 23. Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase.
    Yang X, Sexauer A, Levis M.
    Br J Haematol; 2014 Jan 01; 164(1):61-72. PubMed ID: 24116827
    [Abstract] [Full Text] [Related]

  • 24. All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.
    Ma HS, Greenblatt SM, Shirley CM, Duffield AS, Bruner JK, Li L, Nguyen B, Jung E, Aplan PD, Ghiaur G, Jones RJ, Small D.
    Blood; 2016 Jun 09; 127(23):2867-78. PubMed ID: 27103744
    [Abstract] [Full Text] [Related]

  • 25. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M.
    J Natl Cancer Inst; 2008 Feb 06; 100(3):184-98. PubMed ID: 18230792
    [Abstract] [Full Text] [Related]

  • 26. Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation.
    Fouladi F, Jehn LB, Metzelder SK, Hub F, Henkenius K, Burchert A, Brendel C, Stiewe T, Neubauer A.
    Leuk Lymphoma; 2015 Feb 06; 56(9):2690-8. PubMed ID: 25665465
    [Abstract] [Full Text] [Related]

  • 27. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
    Liu F, Knight T, Su Y, Edwards H, Wang G, Wang Y, Taub JW, Lin H, Sun L, Ge Y.
    Target Oncol; 2019 Jun 06; 14(3):351-364. PubMed ID: 31115744
    [Abstract] [Full Text] [Related]

  • 28. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
    Hormi M, Birsen R, Belhadj M, Huynh T, Cantero Aguilar L, Grignano E, Haddaoui L, Guillonneau F, Mayeux P, Hunault M, Tamburini J, Kosmider O, Fontenay M, Bouscary D, Chapuis N.
    Eur J Haematol; 2020 Nov 06; 105(5):588-596. PubMed ID: 32659848
    [Abstract] [Full Text] [Related]

  • 29. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
    Xu B, Zhao Y, Wang X, Gong P, Ge W.
    Leukemia; 2017 Apr 06; 31(4):913-921. PubMed ID: 27773927
    [Abstract] [Full Text] [Related]

  • 30. Combined inhibition of PI3Kδ and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia.
    He Y, Sun L, Xu Y, Fu L, Li Y, Bao X, Fu H, Xie C, Lou L.
    Cancer Lett; 2018 Apr 28; 420():49-59. PubMed ID: 29409989
    [Abstract] [Full Text] [Related]

  • 31. CXCR4-Mediated Codelivery of FLT3 and BCL-2 Inhibitors for Enhanced Targeted Combination Therapy of FLT3-ITD Acute Myeloid Leukemia.
    Yang J, Zhang P, Mao Y, Chen R, Cheng R, Li J, Sun H, Deng C, Zhong Z.
    Biomacromolecules; 2024 Jul 08; 25(7):4569-4580. PubMed ID: 38869359
    [Abstract] [Full Text] [Related]

  • 32. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
    Naqvi K, Konopleva M, Ravandi F.
    Expert Rev Hematol; 2017 Oct 08; 10(10):863-874. PubMed ID: 28799432
    [Abstract] [Full Text] [Related]

  • 33. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
    Zimmerman EI, Turner DC, Buaboonnam J, Hu S, Orwick S, Roberts MS, Janke LJ, Ramachandran A, Stewart CF, Inaba H, Baker SD.
    Blood; 2013 Nov 21; 122(22):3607-15. PubMed ID: 24046014
    [Abstract] [Full Text] [Related]

  • 34. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
    Djamai H, Berrou J, Dupont M, Kaci A, Ehlert JE, Weber H, Baruchel A, Paublant F, Prudent R, Gardin C, Dombret H, Braun T.
    Leuk Res; 2021 Jan 21; 100():106490. PubMed ID: 33373830
    [Abstract] [Full Text] [Related]

  • 35. Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy.
    Zhang W, Yu G, Zhang H, Basyal M, Ly C, Yuan B, Ruvolo V, Piya S, Bhattacharya S, Zhang Q, Borthakur G, Battula V, Konopleva M, Rice WG, Andreeff M.
    Haematologica; 2023 Jun 01; 108(6):1500-1514. PubMed ID: 36226489
    [Abstract] [Full Text] [Related]

  • 36. Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.
    Zhao J, Niu X, Li X, Edwards H, Wang G, Wang Y, Taub JW, Lin H, Ge Y.
    Oncotarget; 2016 Jun 07; 7(23):34785-99. PubMed ID: 27166183
    [Abstract] [Full Text] [Related]

  • 37. A new cyclin-dependent kinase-9 inhibitor A09-003 induces apoptosis in acute myeloid leukemia cells with reduction of myeloid cell leukemia sequence-1 protein.
    Sim KM, Kim SY, Hwang S, Park S, Lee BR, Nam K, Oh S, Kim I.
    Chem Biol Interact; 2023 Sep 01; 382():110554. PubMed ID: 37271215
    [Abstract] [Full Text] [Related]

  • 38. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
    Lu JW, Wang AN, Liao HA, Chen CY, Hou HA, Hu CY, Tien HF, Ou DL, Lin LI.
    Cancer Lett; 2016 Jul 01; 376(2):218-25. PubMed ID: 27060207
    [Abstract] [Full Text] [Related]

  • 39. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
    Long J, Jia MY, Fang WY, Chen XJ, Mu LL, Wang ZY, Shen Y, Xiang RF, Wang LN, Wang L, Jiang CH, Jiang JL, Zhang WJ, Sun YD, Chang L, Gao WH, Wang Y, Li JM, Hong DL, Liang AB, Hu J.
    Blood; 2020 Apr 23; 135(17):1472-1483. PubMed ID: 32315388
    [Abstract] [Full Text] [Related]

  • 40. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia.
    Jiang X, Mak PY, Mu H, Tao W, Mak DH, Kornblau S, Zhang Q, Ruvolo P, Burks JK, Zhang W, McQueen T, Pan R, Zhou H, Konopleva M, Cortes J, Liu Q, Andreeff M, Carter BZ.
    Clin Cancer Res; 2018 May 15; 24(10):2417-2429. PubMed ID: 29463558
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.